scription factor IFN regulatory factor 3 that induces expression of IFN-ab and IFN-l) (31, 32) were vulnerable to persistent CR6 infection even in the presence of antibiotics (Fig. 4 , B to D; fig. S8 , A and B; and fig. S9 , A to G). Whereas antibiotic treatment prevented persistent infection of control mice inoculated with 10 5 pfu of MNoV ( Fig. 4A and fig. S8A ), some mice lacking components of the IFN-l induction or signaling pathway became persistently infected even at this low dose ( Fig. 4D and fig. S8A , P < 0.01). This vulnerability to MNoV infection did not correspond with differential effects of antibiotics on bacterial depletion in these mutant mice, as shown by 16S rDNA sequencing studies and by experiments in which fecal transplantation from antibiotic-treated mutant mice did not support establishment of persistent infection (fig. S10, A to D). Resistance to MNoV infection in antibiotic-treated control mice was not explained by up-regulation of Ifnlr1 or a selected set of IFN-stimulated genes including Isg15, which has direct antiviral activity against MNoV (33) (fig. S11, A to I).
Our data suggest that the bacterial component of the enteric microbiome plays an essential role in controlling the capacity of a virus to establish persistent infection and that antibiotics can substantially alter the pathogenesis of enteric viral infection. Prior reports have shown that bacterial LPS can alter viral infectivity (22) (23) (24) , but the effects of antibiotics reported here did not require TLR4 or other signaling molecules involved in host responses to LPS. Although the absence of B cells may explain the partial resistance to MNoV infection seen in Rag1 −/− mice (28), adaptive immunity was not required for antibiotic treatment to significantly inhibit persistent MNoV infection. Our results indicate that innate immunity and in particular the IFN-l pathway, is required for the effects of antibiotic treatment on persistent infection. These observations suggest that the bacterial microbiota limits the efficacy of IFN-l-dependent innate immunity or alters some yet-undefined innate immune pathway that renders viruses susceptible to the effects of IFN-l. These data indicate that the clinical use of antibiotics in humans may alter the enteric virome (6, 34) and that the effects of antibiotics in the treatment of infectious diseases may not be entirely attributable to their antibacterial properties. Given the contribution of the virome to host physiology (4, 6) , these data suggest the importance of considering the effects of trans-kingdom interactions for understanding the pathogenesis of infectious diseases.
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Norovirus gastroenteritis is a major public health burden worldwide. Although fecal shedding is important for transmission of enteric viruses, little is known about the immune factors that restrict persistent enteric infection. We report here that although the cytokines interferon-a (IFN-a) and IFN-b prevented the systemic spread of murine norovirus (MNoV), only IFN-l controlled persistent enteric infection. Infection-dependent induction of IFN-l was governed by the MNoV capsid protein and correlated with diminished enteric persistence. Treatment of established infection with IFN-l cured mice in a manner requiring nonhematopoietic cell expression of the IFN-l receptor, Ifnlr1, and independent of adaptive immunity. These results suggest the therapeutic potential of IFN-l for curing virus infections in the gastrointestinal tract.
H uman noroviruses (HNoVs) are a leading cause of gastroenteritis worldwide (1, 2). Asymptomatic fecal shedding of HNoVs may be important epidemiologically, as it provides a reservoir between outbreaks (1, 3-9). Some strains of murine norovirus (MNoV) also establish persistent enteric infection, providing a model for analyzing mechanisms of enteric NoV persistence and immunity in a natural host (1, 10, 11) . Interferons (IFNs) are critical for control of both murine and human NoV replication (12) (13) (14) (15) (16) (17) (18) . Interferon-a (IFN-a) and IFN-b (also called type I IFNs and hereafter IFN-ab), IFN-g (also called type II IFN), and IFN-l (also called type SCIENCE sciencemag.org III IFN or interleukin-28/9) signal through the distinct heterodimeric receptors Ifnar1/Ifnar2, Ifngr1/Ifngr2, and Ifnlr1/Il10rb to regulate gene expression through phosphorylation of Stat proteins (19, 20) . Although the roles of IFNs in control of persistent enteric infection have not been elucidated, it is of interest that IFN-l, but not IFN-ab, is important for control of acute rotavirus infection in the intestine of mice (21) .
To define the role of IFNs in MNoV enteric persistence, we measured levels of the persistent MNoV strain CR6 in different tissues and in feces after oral inoculation of control mice and mice deficient in Ifnar1, Ifngr1, Ifnlr1, or Stat1 (Fig. 1) (also see supplementary materials and methods). As expected, Ifnar1 and Stat1 were important for limiting replication in the spleen and mesenteric lymph node (MLN) (12, 13, 16, 17) , whereas Stat1 rather than Ifnar1 controlled levels of replication in the colon (Fig. 1A) , suggesting that IFN-ab responses did not explain Stat1-dependent control of replication in the intestine. Consistent with this, comparison of the requirement for each IFN receptor in control of fecal shedding revealed that only Stat1 and Ifnlr1 limited levels of fecal shedding of MNoV (Fig. 1B) . Furthermore, we observed increased fecal shedding compared with controls in Ifnlr1 −/− but not Ifnar1 −/− mice over 35 days of infection (Fig. 1C) .
To define the basis for the intestine-specific role of IFN-l in control of enteric persistence, we inoculated mice with the persistent MNoV strain CR6 or the nonpersistent MNoV strain CW3 and compared viral replication and induction of IFN-l and IFN-b in Peyer's patches, MLNs, and the colon. As expected, CW3 replicated preferentially in MLN, CR6 and CW3 replicated equivalently in Peyer's patches, and CR6 replicated preferentially in colon ( fig. S1) (11, 22) . CW3 induced both IFN-b and IFN-l (Fig. 2, A and B) in MLN and Peyer's patches. In contrast, CR6 did not induce detectable IFN-b or IFN-l mRNA in any organ, despite the high level of replication in the intestine (Fig. 2, A and B) . Both strains induced equivalent amounts of IFN-b from bone marrow-derived dendritic cells (BMDCs) in vitro ( fig. S2 ). The capacity of strain CW3 to infect systemic organs maps to the protruding domain of the viral capsid protein (11, 22) 
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, hereafter D94E) in the NS1-2 protein confers the capacity for enteric persistence upon CW3 (11, 23) . In chimeric viruses, the presence of the entire CW3 capsid gene or the protruding domain of the CW3 capsid gene correlated with IFN-b and IFN-l induction ( fig. S3, A to F) . Furthermore, in CW3-derived viruses carrying the NS1-2 D94E mutation that confers persistence (CW3 D94E ), the presence of the CR6 capsid lessened IFN-b and IFN-l induction in MLNs despite similar levels of viral replication (Fig. 2C) . This phenotype allowed us to use a chimeric virus to test the hypothesis that IFN-l responses are required for prevention of persistence. The CW3 D94E strain is capable of efficiently establishing enteric persistence only at low doses ( fig. S4 ). When control mice were inoculated with a high dose of CW3 D94E , many mice failed to establish persistence ( fig. S4 and Fig. 2D ). This failure of CW3 D94E to persist was rescued either by the CR6 capsid protein, which is associated with diminished IFN-b and IFN-l responses (fig.  S4 ), or by infection of Ifnlr1 −/− mice (Fig. 2D) .
Persistence of parental CW3, lacking intestinal tropism conferred by the D94E mutation, was not rescued in Ifnlr1 −/− mice ( fig. S5 ). These data indicate that induction of IFN-l interferes with the establishment of enteric MNoV persistence. These findings suggest a primary role for IFN-l in control of enteric MNoV persistence. Consistent with this, intraperitoneal treatment of mice with IFN-l 1 day after oral inoculation with CR6 prevented persistent enteric MNoV infection (Fig. 3A) . When cured mice were rechallenged with CR6 2 weeks later, persistent infection was established (Fig. 3B) , indicating that IFN-l acted by stimulating innate immunity rather than promoting adaptive immunity. These data also indicate that therapeutic levels of IFN-l wane in animals within 2 weeks of administration. over time in feces (C). Data shown are pooled from at least two independent experiments, with each point representing an individual animal in (A) and (B). Points in (C) represent at least four animals pooled from two to four independent experiments. Dashed lines represent limit of detection. Statistical significance was determined by one-way (A and B) or two-way (C) analysis of variance (ANOVA). n.s., not significant (P > 0.05); *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Error bars in (C) denote SD. . Data in (A) to (C) are pooled from three independent experiments for a total of three to four mice per time point. Data points in (D) are individual mice pooled from three independent experiments. Dashed lines represent limit of detection. Statistical significance was determined by two-way ANOVA (A and B) or Mann-Whitney test (C and D). n.s. indicates P > 0.05; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Error bars in (A) and (B) denote SD. To determine if therapeutic IFN-l was effective against established persistent infection, we treated mice with IFN-l at 21, 23, and 25 days after oral inoculation with CR6, a time at which stable enteric persistence is established (11) . Shedding of virus into the feces was reduced~100-fold within 2 days and was undetectable within 1 week (Fig. 3C) . Analysis of viral genomes in tissues 2 weeks after IFN-l treatment revealed reduced or undetectable levels of virus in the MLN and undetectable virus levels in the colon (fig. S6) . As little as a single 1-mg dose of IFN-l was sufficient to clear persistent MNoV (fig. S7A ). Ifnlr1 was required for IFN-l activity, whereas Ifnar1 was dispensable ( Fig. 3C and fig. S6 ), indicating that IFN-l does not require IFN-ab signaling to eliminate enteric persistence.
Whereas MNoV is known to replicate in immune cells, attempts to cultivate MNoV or HNoV in epithelial cells have not been successful (1, 24) . Treatment of cultured BMDCs with IFN-b, but not IFN-l, inhibited MNoV replication (Fig. 4A ). Taken together with previously published data (21, (25) (26) (27) , this result raised the possibility that IFN-l acts on nonhematopoietic cells to control enteric persistence. Experiments in reciprocal bone marrow chimeras revealed that the control of fecal MNoV levels (Fig. 4B ) and the capacity for IFN-l to cure enteric persistence (Fig. 4C ) mapped to the nonhematopoietic rather than radiation-sensitive hematopoietic cells. These data were consistent with an Ifnar1-independent effect of IFN-l on enteric persistence through stimulation of immunity via signaling in radiation-insensitive cells.
Despite the capacity of mice to mount protective adaptive immune responses to MNoV infection (28, 29) , their susceptibility to reinfection after treatment with IFN-l (Fig. 3B) 4D ). All Rag1 −/− mice and the majority of control mice remained MNoV-free for 35 days after treatment, well after therapeutic levels of IFN-l waned (Fig. 3B) . The absence of infectious MNoV was confirmed by fecal transplantation from IFN-l-cleared
S7, B and C).
Together, these data demonstrate that IFN-l treatment both prevents and cures established enteric persistence of MNoV in the absence of an adaptive immune response. Our study establishes the importance of IFN-l in innate immunity to persistent enteric viral infection. Establishment of persistent enteric infection by certain strains of MNoV was related to failure to induce IFN-l responses. Whereas MNoV replicates in hematopoietic cells, IFN-l was found to act on nonhematopoietic cells, suggesting that the mechanism of action is indirect. The efficacy of IFN-l in the prevention and cure of enteric persistence did not require adaptive immunity. These findings provide a different view of the immune system because it is generally believed that the development of an adaptive immune response is required for clearance of viral infection by antigen-specific targeting. One implication of our findings is that immune therapies may be able to control persistent virus infection regardless of their effects on adaptive immune responses. We propose that this is an example of sterilizing innate immunity wherein viral clearance can be determined by immune responses apart from adaptive immunity. A similar observation of viral clearance by an independent mechanism of a second enteric virus, rotavirus, supports the existence of sterilizing innate immunity (30) . Analogously, metazoan organisms lacking adaptive immune systems are probably capable of clearing some pathogens and preventing persistent infection. We speculate that evolutionarily conserved innate immune mechanisms with sterilizing potential exist, perhaps with particular importance in protection against persistent infection at mucosal surfaces such as the intestine. 
